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Abstract
Prior studies suggest an association between Vitamin K antagonists (VKA) and
cerebral microbleeds (CMBs); less is known about nonvitamin K oral anticoag-
ulants (NOACs). In this observational study we describe CMB profiles in a
multicenter cohort of 89 anticoagulation-related intracerebral hemorrhage
(ICH) patients. CMB prevalence was 51% (52% in VKA-ICH, 48% in NOAC-
ICH). NOAC-ICH patients had lower median CMB count [2(IQR:1–3) vs. 7(4–
11); P < 0.001]; ≥5 CMBs were less prevalent in NOAC-ICH (4% vs. 31%,
P = 0.006). This inverse association between NOAC exposure and high CMB
count persisted in multivariable logistic regression models adjusting for poten-
tial confounders (OR 0.10, 95%CI: 0.01–0.83; P = 0.034).
Introduction
Cerebral microbleeds (CMBs) are cerebral small vessel
disease markers identified in blood-sensitive brain MRI
sequences (gradient-recalled echo [GRE] or susceptibility-
weighted imaging (SWI).1 They correspond to diverse
underlying pathological processes. While hypertensive2 or
cerebral amyloid angiopathy-related microhemorrhages
are the most commonly associated conditions, ischemic
processes such hemorrhagic transformation of ischemic
microinfarcts and extravasation of red thrombi might also
have similar imaging appearance CMBs have been linked
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to increased incident risk of both ischemic and hemor-
rhagic stroke.2 Although ischemic strokes are more fre-
quent in terms of absolute event rates, the association of
CMB presence with incident intracerebral hemorrhage
(ICH) for the individual patient is more potent, especially
in those with higher CMB burden.3 Thus, CMBs are rec-
ognized as a potentially useful prognostic of ICH espe-
cially in high-risk patients exposed to therapeutic oral
anticoagulation.3,4
Less is known regarding the relationship between oral
anticoagulation and the pathogenesis of CMBs. Data
regarding Vitamin K antagonists (VKAs) and CMBs gen-
erally suggest higher risk, especially among those with
highly variable international normalized ratio (INR).5,6
Data regarding nonvitamin K oral antiocoagulants
(NOACs) are scarce and suggest no overall association
between NOAC exposure and CMB incidence or burden.7
Notably, a recent multicenter study reported higher CMB
prevalence in patients experiencing ICH than ischemic
stroke while taking NOACs.8 We undertook this observa-
tional, cross-sectional study to characterize the prevalence
and burden of CMBs in patients with symptomatic anti-
coagulation-associated ICH and examine potential differ-
ences in VKA versus NOAC-exposed patients.
Methods
Patient population
This is a retrospective analysis of two prospectively enrolled
consecutive patient cohorts of nontraumatic ICH and posi-
tive history of oral anticoagulant intake in 15 participating
tertiary-care stroke centers during a 2-year period (August
2015–July 2016 and August 2016–July 2017).9,10 Patient
characteristics and outcome have been described in detail
previously9,10 and are available in the online supplement
(Table S1). Briefly, the definition of VKA-related ICH
required effective use of a VKA with an international nor-
malized value of >1.5 on hospital admission, while the defi-
nition of NOAC-related ICH required confirmed ingestion
of the relevant NOAC during the last 24 h before the index
event. Patients with major head trauma or known underly-
ing structural or vascular cause of ICH were excluded from
further evaluation. We also excluded patients with hemor-
rhagic transformation of ischemic infarcts and patients
with pure intraventricular hemorrhage. Lastly, we excluded
patients without baseline MRI with available blood-sensi-
tive sequences allowing CMB detection.
Imaging characteristics and criteria
We defined CMBs according to the Standards for Report-
ing Vascular changes on neuroimaging (STRIVE)
consensus criteria.1 We recorded magnet strength (1.5 vs.
3T) and type of sequence used. Further details on CMB
reading are available in the online supplement. MRI was
performed in the acute phase (during the admission for
the index ICH). Images were reviewed by experienced
vascular neurologists at each center, blinded to anticoagu-
lation exposure and official Neuroradiologist read for
both CMB presence and ICH location. Formal Neuroradi-
ological interpretation was used to corroborate ICH loca-
tion.
Statistical analyses
Continuous variables are presented as median with
interquartile range, whereas categorical variables are pre-
sented as percentages. Statistical comparisons between dif-
ferent subgroups were performed using the Pearson’s v2
test and Mann–Whitney U test, where appropriate.
Multivariable logistic regression analyses were per-
formed on the association of baseline characteristics with
the presence of five or more cerebral microbleeds in base-
line neuroimaging.11 In univariable models of all baseline
characteristics a threshold of P < 0.1 was used to identify
candidate variables for inclusion in the multivariate
regression models that tested statistical significance
hypothesis using the likelihood ratio test with an alpha
value of 0.05. We also performed sensitivity univariable/
multivariable logistic regression analyses after excluding
patients with no presence of cerebral microbleeds on
baseline neuroimaging. Finally, we also performed
adjusted for baseline ICH volume analyses on the proba-
bilities of hematoma expansion and ICH volume more
than 30 cm3 at the follow-up neuroimaging in 24 h
according to baseline CMB burden (<5 CMBs or ≥5
CMBs).
We used Stata Statistical Software Release 13 for Win-
dows (College Station, TX, StataCorp LP) for all analyses.
Results
Our two previous cohorts comprised a total of 109
NOAC-related and 248 VKA-related ICHs. Of these, a
total of 89 patients (25 NOAC-, 64 VKA-associated)
received brain MRI with GRE or SWI sequences allowing
CMB detection. Compared to those who did not receive
MRI (Table S1), included patients had higher median
BMI (30 vs. 27 kg/m2, P = 0.002), were less likely to have
hypertension (89% vs. 97%; P = 0.002), hyperlipidemia
(52% vs. 65%; P = 0.03), and coronary artery disease
(28% vs. 40%; P = 0.04); otherwise there were no signifi-
cant differences. Patient characteristics according to anti-
coagulant type are summarized in Table 1. NOAC-ICH
patients were older (median age 78 [70–81] years vs. 70
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[60–77] years; P = 0.005), had higher CHA2DS2-VASc
score (4[4–6] vs. 4[3–5]); P = 0.017, and were less likely
to have lobar ICH location (28% vs. 58%; P = 0.001).
A total of 45 patients (51%) had ≥ 1 CMB. There
was no difference between VKA- and NOAC- ICH (52%
vs. 48%; P = 0.763; Table 1). However, the median CMB
number was significantly lower in NOAC-ICH patients (2
[1–3] vs. 7[4–11]; P < 0.001 (Table 1 and Fig. 1). A total
of 21 patients had high CMB burden (≥5 CMB). Their
characteristics are summarized in Table S2. High CMB
burden (≥ 5 CMBs) was less prevalent in NOAC-ICH
patients (31% vs. 4%; P = 0.006, Table 1). In contrast,
high CMB burden was more common in younger patients
and in patients who underwent 3 Tesla MRI (Table 2).
This inverse association between NOAC (vs. VKA) expo-
sure and high CMB count persisted in multivariable logis-
tic regression models adjusting for potential confounders
including demographics, risk factors, laboratory and brain
imaging parameters: (OR 0.10, 95%CI:0.01–0.83;
P = 0.034; Table 2). In sensitivity analyses, four factors
were associated with high CMB burden in this sensitivity
analysis: age, NOAC pretreatment, antiplatelet pretreat-
ment and MRI strength (Table S3). Pretreatment with
NOACs was independently related to lower odds of high
CMB burden (OR 0.02, 95%CI: 0.01–0.25; P = 0.006) in
the sensitivity analysis (Table S3).
Table 1. Baseline characteristics and outcomes according to the type of oral anticoagulant treatment
Variable VKA (n = 64) NOAC (n = 25) P-value
Baseline clinical characteristics
Age (years, median, IQR) 70 (60–77) 78 (70–81) 0.005
Males (%) 65.6% 52.0% 0.234
BMI (median, IQR) 30 (25–33) 27 (17–34) 0.133
CHA2DS2-VASc score (median, IQR) 4 (3–5) 4 (4–6) 0.017
HAS-BLED score (median, IQR) 3 (2–3) 2 (2–4) 0.917
Hypertension (%) 92.1% 96.0% 0.519
Diabetes (%) 42.2% 32.0% 0.376
Hyperlipidemia (%) 50.0% 48.0% 0.865
Heart failure (%) 21.9% 12.0% 0.287
Current smoking (%) 10.9% 4.0% 0.304
Coronary artery disease (%) 31.2% 32.0% 0.945
Chronic kidney disease (%) 17.2% 16.0% 0.893
Prior history of ischemic stroke (%) 29.7% 24.0% 0.592
Prior history of intracerebral hemorrhage (%) 6.2% 0% 0.201
Statin pretreatment (%) 67.2% 48.0% 0.094
Antiplatelet pretreatment (%) 43.7% 36.0% 0.505
NIHSS admission (median, IQR) 5 (3–18) 6 (3–12) 0.487
GCS admission (median, IQR) 14 (8–15) 14 (13–15) 0.257
SBP admission (mmHg, median, IQR) 163 (147–190) 175 (141–200) 0.435
DBP admission (mmHg, median, IQR) 94 (80–99) 91 (74–98) 0.464
Baseline Laboratory values
INR admission (median, IQR) 2.4 (1.8–3.6) 1.2 (1.1–1.6) <0.001
aPTT admission (sec, median, IQR) 39 (33–42) 30 (28–32) <0.001
Platelet count 9103/lL (median, IQR) 192 (159–259) 218 (184–270) 0.217
CrCl on admission (ml/min, median, IQR) 60 (44–70) 60 (45–75) 0.291
Baseline neuroimaging findings
Lobar hemorrhage (%) 57.8% 28.0% 0.001
Intraventricular hemorrhage (%) 35.9% 32.0% 0.726
Baseline ICH volume (cm3, median, IQR) 11.3 (5.1–26.3) 4.9 (2.1–22.1) 0.051
ICH score (median, IQR) 1 (1–2) 1 (1–2) 0.635
Severe ICH (%)1 14.5% 16.0% 0.861
CMB presence (%) 51.6% 48.0% 0.763
CMB number (median, IQR)2 7 (4–11) 2 (1–3) <0.001
CMB ≥5 (%) 31.2% 4.0% 0.006
CMB ≥10 (%) 17.1% 4.0% 0.102
3T MRI 39.1% 36.0% 0.789
SWI sequence 6.2% 0% 0.201
1Defined as ICH score ≥2.
2After excluding patients without CMB presence.
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Discussion
In this cross-sectional observational study of anticoagula-
tion-associated ICH, we documented an overall preva-
lence of CMBs of 51%. Although CMB prevalence was
well-balanced between VKA and NOAC-ICH, NOAC-ICH
patients had significantly lower CMB burden, both in
median number and when dichotomized as <5 versus ≥5
CMBs. These associations remained significant after
adjusting for potential confounders.
The observed CMB prevalence of ~50% is significantly
higher than the frequency reported in population-based
studies12–14 and studies in ischemic stroke patients3 which
range from 8.8 to 23%, with tendency to increase with
age. However, this prevalence is comparable or lower than
CMB frequency reported in ICH cohorts which often
p<0.001
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Figure 1. Distribution of cerebral microbleeds in baseline neuroimaging between patients with history of oral anticoagulation pretreatment with
either vitamin K antagonists or nonvitamin K antagonist oral anticoagulants.
Table 2. Univariable and multivariable logistic regression analyses on the association of baseline characteristics with the presence of five or more
cerebral microbleeds in baseline neuroimaging
Univariable analysis Multivariable analysis
OR (95%CI) P OR (95%CI) P
Age (years) 0.94 (0.89, 0.98) 0.011 0.94 (0.89, 0.99) 0.031
Males (%) 1.28 (0.48, 3.40) 0.616 – –
BMI 1.03 (0.97, 1.09) 0.338 – –
Hypertension 1.59 (0.17, 14.40) 0.681 –
Diabetes 1.21 (0.45, 3.27) 0.705 – –
Hyperlipidemia 1.50 (0.56, 4.02) 0.421 – –
Heart failure 0.99 (0.29, 3.46) 0.994 – –
Current smoking 2.10 (0.46, 9.64) 0.340 – –
Coronary artery disease 0.61 (0.20, 1.88) 0.390 – –
Kidney failure 1.81 (0.54, 6.06) 0.335 – –
Prior history of ischemic stroke 1.39 (0.48, 3.99) 0.542 – –
Prior history of intracerebral hemorrhage 3.47 (0.46, 26.32) 0.228
Statin pretreatment 1.32 (0.47, 3.69) 0.600 – –
Antiplatelet pretreatment 0.48 (0.16, 1.38) 0.172 – –
NOAC pretreatment 0.09 (0.01, 0.72) 0.024 0.10 (0.01, 0.83) 0.034
Admission SBP 0.99 (0.98, 1.01) 0.575 – –
Admission DBP 1.02 (0.99, 1.05) 0.191 – –
Lobar hemorrhage 1.17 (0.44, 3.11) 0.758 – –
3T MRI 4.80 (1.68, 13.67) 0.003 6.42 (1.96, 21.03) 0.002
SWI sequence 3.47 (0.46, 26.32) 0.228 – –
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exceeds 60%,15 using similar MRI strength and technique.
This finding is counterintuitive, as one would expect
higher prevalence of cerebral hemorrhagic complications,
including CMBs, in those exposed to oral anticoagulation.
Moreover, although the absolute CMB count in prior
similar studies is not always reported, the proportion of
patients with high CMB count (defined as ≥5 CMBs) in a
study of pooled hospital-based ICH cohorts is estimated
very similar to our observed frequency of ~24%. Thus,
although higher CMB burden is strongly associated with
future ICH risk in patients receiving oral anticoagulation,
our study does not provide evidence for increased crude
CMB prevalence or burden in patients exposed to thera-
peutic anticoagulation compared to historical controls;
this finding should be viewed with caution due to lack of
a nonanticoagulated control group in this study.
Closer examination stratifying by anticoagulation type
reveals significantly lower burden of CMBs in NOAC-
ICH patients, despite older age. This is in line with previ-
ous studies in non-ICH atrial fibrillation Asian patient
cohorts that have found no association between NOAC
exposure and increased CMB burden, which was similar
to nonanticoagulated controls.7,16 It is also in line with
well-established lower overall hemorrhagic risk of NOACs
compared to VKAs.17 Given the significantly higher pro-
portion of lobar ICH in the VKA-exposed patients,
another plausible explanation for this imbalance in CMB
burden is that this subgroup had a higher prevalence of
cerebral amyloid angiopathy (CAA), resulting in higher
CMB burden. On the other hand, it should be noted that
patients pretreated with NOACs were older than patients
pretreated with VKA and this observation does not sup-
port the hypothesis of a higher CAA prevalence in the
VKA group.
This finding also suggests that the interaction between
CMB and ICH risk might not be clinically consequential
in those exposed to NOAC, making NOAC a more suit-
able choice in patients with higher CMB burden in need
for anticoagulation. In the large prospective observational
CROMIS-2 study there was a significantly lower propor-
tion of NOAC-exposed patients among those who suf-
fered an ICH compared to VKA exposure (14% vs. 86%)
over a 2-year follow-up period, although this did not
reach statistical significance (P = 0.071) due to the low
number of events.3 Similarly, in a secondary analysis of
the NAVIGATE-ESUS trial (Shoamanesh et al., oral pre-
sentation in International Stroke Conference 2019), the
risk of ICH in the rivaroxaban-allocated group was not
affected by CMB presence compared to aspirin.
Our study is not without limitations. It was retrospec-
tive, observational, and treatment bias might have affected
anticoagulation therapy allocation. The final sample size
was small, especially with regards to the NOAC group.
External validation in a larger cohort is necessary Given
the cross-sectional nature of this analysis it is not possible
to ascertain whether there is a causative link between
anticoagulation exposure and CMB formation or whether
CMB presence and anticoagulation exposure act synergis-
tically to increase the risk of hemorrhage. Approximately
25% of the entire cohort received MRI and was available
for analysis. Despite small imbalances in baseline cardio-
vascular risk factor prevalence, we found no evidence of a
systematic selection bias with regards to parameters of
interest, including anticoagulation type, concomitant
medications, ICH severity and overall CHA2DS2-VASc
and HAS-BLED score (Table S1). MRI protocols and
strengths which are well-known to affect the sensitivity of
CMB detection were heterogeneous among participating
centers. However, both 3T MRI and SWI sequence use
were evenly distributed between anticoagulation allocation
groups (Table 1) and the association between NOAC-ICH
and lower CMB burden remained significant after adjust-
ing for magnet strength. We had no information regard-
ing duration of exposure to anticoagulation which might
be an important factor determining development of
CMBs. However, we note that NOAC-ICH patients were
older and with higher CHA2DS2-VASc score; it is plausi-
ble that they might have been exposed to VKA and subse-
quently changed to NOAC, which would further highlight
lower risk of CMB formation associated with NOAC. We
do not have information regarding CMB anatomical loca-
tion, which is a shortcoming subtracting granularity from
our findings, given that different CMB location implies
differential underlying pathology.13,14
In conclusion, we documented similar prevalence but
significantly higher burden of CMBs in VKA compared to
NOAC exposure, in a cohort of 89 patients with anticoag-
ulation-related ICH. Results of additional ongoing
prospective studies (Intracerebral Hemorrhage Due to
Oral Anticoagulants: Prediction of the Risk by Magnetic
Resonance (HERO) https://clinicaltrials.gov/ct2/show/
NCT02238470) and Cerebral Microbleeds During NOACs
or Warfarin Therapy in NVAF Patients With Acute
Ischemic Stroke (CMB-NOW) https://clinicaltrials.gov/
ct2/show/NCT02356432) are expected to further refine
our understanding of the interaction between CMBs and
anticoagulant therapy.
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